Compare HCTI & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCTI | LNAI |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4M | 12.4M |
| IPO Year | 2021 | 2014 |
| Metric | HCTI | LNAI |
|---|---|---|
| Price | $0.69 | $1.42 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 36.4K |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,891,000.00 | N/A |
| Revenue This Year | $179.58 | N/A |
| Revenue Next Year | $4.39 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 18.77 | N/A |
| 52 Week Low | $0.14 | $0.15 |
| 52 Week High | $9.97 | $5.02 |
| Indicator | HCTI | LNAI |
|---|---|---|
| Relative Strength Index (RSI) | 39.88 | 25.99 |
| Support Level | $0.65 | $0.26 |
| Resistance Level | $1.01 | $2.58 |
| Average True Range (ATR) | 0.23 | 0.25 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 1.79 | 7.39 |
Healthcare Triangle Inc is a healthcare information technology company focused on advancing industry-transforming solutions in the sectors of cloud services, data science, and professional and managed services for the healthcare and life sciences industry. The company reinforces healthcare progress through technology and extensive industry know-how. HTI supports healthcare providers and payors, hospitals, and Pharma Life Sciences organizations in their efforts to improve health outcomes by enabling the adoption of new technologies, data enlightenment, business agility, and accelerated response to immediate business needs and competitive threats. It provides services under three operating segments: Software Services, Managed Services, and Support and Corporate & others.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.